SK Chemicals’ hemophilia treatment, a biopharmaceutical new drug, is about to be approved in the U.S.

Published: 2015-07-31 13:38:03

Updated: 2015-07-31 13:38:03

The U.S. approval procedure of the hemophilia treatment developed by a domestic pharmaceutical company has been accelerated.

SK Chemicals(President Man-hoon Park) announced on the 29^th that it has completed application for the FDA’s marketing approval of its self-developed hemophilia treating biopharmaceutical new drug substance ‘NBP601.’

Developed by the own technology of SK Chemicals and ex...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.